-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37th Annual Meeting of The Society for Immunotherapy of Cancer (SITC) highlighting preclinical data for AFVT-2101 (previously AFM32).
AFVT-2101 is a tetravalent, bispecific Innate Cell Engager (ICE®) that bridges folate receptor alpha (FRα) on tumor cells with CD16A expressing innate immune cells, to induce potent and selective targeted tumor cell killing. FRα is a tumor-associated antigen which is highly overexpressed on a variety of epithelial tumors.
The following poster will be presented live at SITC on November 11th:
Title: AFVT-2101, an innate immune-cell engager that selectively targets FOLR1 expressing tumor cells to safely harness potent anti-cancer responses
Poster #: 1212
Authors: Ahmad Trad, Michael Tomaszowski, Josef Caslavsky, Robert Freitag, Sudhir Penugonda, Keith Haan, Markus Rohrwild, Daniel O'Shannessy, Jana Siegler, Peter Sandy, Eric Gaukel, Daniela Penston, Zoë Johnson
The poster shows that AFVT-2101 binds selectively to CD16A (both 158V and 158F variants). Physiological levels of competing IgG do not alter binding efficacy. AFVT-2101 induces potent and selective ADCC, even on FRα low expressing cell lines. AFVT-2101 is also shown to induce efficient ADCP in vitro. Co-culture of PBMCs, tumor cells and AFVT-2101 showed concentration-dependent release of pro-inflammatory cytokines (IFNγ, IP-10, TNFα) and minimal off-target cytokine release, confirming a potent but safe in vitro profile of AFVT-2101.
About ICE molecules
Innate Cell Engager (ICE®) molecules are designed to bivalently bind CD16A+ cells of the innate immune system and a tumor associated antigen, inducing potent, tumor-directed cytotoxicity via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
About Affivant
Affivant, a Roivant Sciences company, is dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer. Our innovative bi-specific innate cell engagers are designed to target specific patient populations as powerful monotherapies and combination treatments. AFVT-2101 is currently in IND-enabling studies.
For more information, visit .
Contact:
Zoë Johnson, Chief Scientific Officer
zoe.johnson@affivant.com
NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37th Annual Meeting of The Society for Immunotherapy of Cancer (SITC) highlighting preclinical data for AFVT-2101 (previously AFM32).
紐約和瑞士巴塞爾,2022年11月10日(Global Newswire)--致力於開發新的免疫腫瘤學方法以激活並使先天免疫系統抗擊癌症的生物技術公司Affivant將在37這是癌症免疫治療學會(SITC)年度會議,重點介紹AFVT-2101(以前的AFM32)的臨牀前數據。
AFVT-2101 is a tetravalent, bispecific Innate Cell Engager (ICE®) that bridges folate receptor alpha (FRα) on tumor cells with CD16A expressing innate immune cells, to induce potent and selective targeted tumor cell killing. FRα is a tumor-associated antigen which is highly overexpressed on a variety of epithelial tumors.
AfVT-2101是一種四價、雙特異性的天然細胞激活劑(ICE®),將腫瘤細胞上的葉酸受體α(FRα)與表達CD16A的天然免疫細胞連接起來,誘導有效和選擇性的靶向腫瘤細胞殺傷。FRα是一種腫瘤相關抗原,在多種上皮性腫瘤中高表達。
The following poster will be presented live at SITC on November 11th:
以下海報將於11月11日在SITC現場展示這是:
Title: AFVT-2101, an innate immune-cell engager that selectively targets FOLR1 expressing tumor cells to safely harness potent anti-cancer responses
標題:AfVT-2101,一種先天免疫細胞激活劑,選擇性靶向表達FOLR1的腫瘤細胞,以安全地利用強大的抗癌反應
Poster #: 1212
發信人:1212
Authors: Ahmad Trad, Michael Tomaszowski, Josef Caslavsky, Robert Freitag, Sudhir Penugonda, Keith Haan, Markus Rohrwild, Daniel O'Shannessy, Jana Siegler, Peter Sandy, Eric Gaukel, Daniela Penston, Zoë Johnson
作者:艾哈邁德·特拉德,邁克爾·託馬佐夫斯基,約瑟夫·卡斯拉夫斯基,羅伯特·弗雷塔格,蘇迪爾·佩努貢達,基思·漢,馬庫斯·羅威爾德,Daniel·奧尚尼斯,賈娜·西格勒,彼得·桑迪,埃裏克·高克爾,丹妮拉·彭斯頓,佐伊·約翰遜
The poster shows that AFVT-2101 binds selectively to CD16A (both 158V and 158F variants). Physiological levels of competing IgG do not alter binding efficacy. AFVT-2101 induces potent and selective ADCC, even on FRα low expressing cell lines. AFVT-2101 is also shown to induce efficient ADCP in vitro. Co-culture of PBMCs, tumor cells and AFVT-2101 showed concentration-dependent release of pro-inflammatory cytokines (IFNγ, IP-10, TNFα) and minimal off-target cytokine release, confirming a potent but safe in vitro profile of AFVT-2101.
海報顯示,AFVT-2101選擇性地與CD16A(158V和158F變種)結合。競爭的免疫球蛋白的生理水平不會改變結合效率。即使在FRα低表達的細胞系中,AfVT2101也能誘導出強大的、選擇性的ADCC。AfVT-2101也被證明可以誘導有效的ADCP體外培養。PBMC、腫瘤細胞和AFVT2101的共培養顯示出濃度依賴的促炎細胞因子(幹擾素γ、IP-10、腫瘤壞死因子α)的釋放和最小的非靶向細胞因子的釋放,證實了一種有效但安全的體外培養AFVT-2101的概況。
About ICE molecules
關於冰分子
Innate Cell Engager (ICE®) molecules are designed to bivalently bind CD16A+ cells of the innate immune system and a tumor associated antigen, inducing potent, tumor-directed cytotoxicity via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
先天細胞激活者(ICE®)分子被設計成二價結合先天免疫系統的CD16A+細胞和腫瘤相關抗原,通過抗體依賴的細胞毒性(ADCC)和抗體依賴的細胞吞噬作用(ADCP)誘導強大的腫瘤導向的細胞毒作用。
About Affivant
關於阿菲凡特
Affivant, a Roivant Sciences company, is dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer. Our innovative bi-specific innate cell engagers are designed to target specific patient populations as powerful monotherapies and combination treatments. AFVT-2101 is currently in IND-enabling studies.
Affivant是Roivant Sciences的一家公司,致力於開發新的免疫腫瘤學方法,以激活並使先天免疫系統能夠抗擊癌症。我們創新的雙特定天然細胞活躍器旨在針對特定的患者羣體,作為強大的單一療法和聯合療法。AfVT-2101目前正在進行啟用IND的研究。
For more information, visit .
有關更多信息,請訪問。
Contact:
聯繫方式:
Zoë Johnson, Chief Scientific Officer
zoe.johnson@affivant.com
首席科學官佐伊·約翰遜
郵箱:zoe.johnson@affivant.com
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧